


Renewing our commitment to our corporate partners.

Dear CAP partner,

Your investment in SIR's mission to improve lives through image-guided therapy comes at a time of unprecedented strength and renewed excitement in interventional radiology, the society and foundation.

Our success is due in large part to your generous support. While there is no doubt that 2019 will bring continued advances at SIR, it is of utmost importance that we renew our commitment to you, our CAP partner, and remain laser-focused on supporting your near and long-term strategic priorities.

5,210 TOTAL ATTENDANCE



**SIR 2019 Austin:
Major league specialty
hits a homerun**

SIR 2019 may be remembered as a tipping point in the quantitative and qualitative growth of the IR specialty. The “Called up to the Major Leagues” plenary session highlighted the early successes of IR, upon which a more robust and refined specialty society is rapidly being built. Landmark participation and media coverage were consistent with the groundswell of growth and interest in advancing IR.

60+ countries represented

1,750+ abstracts submitted

6,400,000+ Facebook and Twitter impressions

636,000,000+ trade and consumer media impressions

IMPACT: The SIR Annual Scientific Meeting continues to serve as the seminal professional event for interventional radiologists in medical school, training or practice.

ACTION: Call for abstracts for SIR 2020 in Seattle opens on July 16. Contact [Jonas Nash](#), SIR director of corporate relations for questions or more information.

30 years of illuminating innovation SIR Foundation Gala

SIR Foundation celebrated 30 years of illuminating innovation at its gala on March 24, which honored John Abele, FSIR, with the 2019 Frederick S. Keller, MD, Philanthropy Award. The event featured guest speaker

Rahul A. Sheth, MD, from the MD Anderson Cancer Center, who has received three SIR Foundation grants and recently obtained NIH funding. SIR Foundation Chair Jeremy C. Durack, MD, MS, FSIR, of Memorial Sloan Kettering Cancer Center, and Development Division and Gala Chair Theresa M. Caridi, MD, FSIR, of MedStar Georgetown University Hospital, served as co-hosts for the evening.



IMPACT: The 2019 Gala raised \$553,000 for research in IR. Thank you to the 2019 Gala corporate partners for their incredible generosity: Medtronic, BD, BTG, Argon Medical Devices, Boston Scientific, Stryker, Cook Medical, Endocare, Guerbet and Siemens Healthineers.

ACTION: To become a 2020 Gala sponsor, contact [Terrienne Zeifman](#), SIR Foundation director of development.

Advancing research on immunotherapy and prostate artery embolization

SIR Foundation convened its inaugural research summit on immunotherapy on March 27, at the SIR Annual Scientific Meeting. Together, IRs, medical and radiation oncologists, and industry partners shared their expertise to develop a list of research priorities in immunotherapy and discuss future opportunities for collaboration. SIR Foundation is grateful to Joseph P. Erinjeri, MD, PhD, from Memorial Sloan Kettering Cancer Center, for leading our first research summit.

SIR Foundation's research consensus panel (RCP) on prostate artery embolization (PAE) took place on April 15, 2019. The panel consisted of international subject matter experts in PAE from interventional radiology and urology and evaluated the current status of PAE research to determine the highest priority research needs in PAE. The panelists also discussed collaboration between urologists and IR in improving the guidelines for PAE. SIR Foundation would like to thank Clifford R. Davis, MD, from the University of South Florida, and Jafar Golzarian, MD, FSIR, from the University of Minnesota, for leading this important expert meeting.

IMPACT: SIR Foundation's multi-disciplinary forums facilitate the evaluation, prioritization and early planning for critical topics such as PAE and immunotherapy. Both meetings will result in proceedings publications in the *Journal of Vascular and Interventional Radiology (JVIR)*.

ACTION: Learn more about [SIR Foundation research activities](#).

The IR Residency Match: Competition

March 15 marked the fourth year of interventional radiology participating in the NRMP Main Residency Match. Once again, 100 percent of the available integrated IR residency positions were filled. IR was one of only six specialties in the Main Residency Match with more than 30 positions that filled all available slots.

- 21 programs matched applicants into 37 PGY-1 categorical (C) positions (269 total applicants)
- 61 programs matched applicants into 113 PGY-2 advanced (A) positions (319 total applicants)
- 1 program matched an applicant into 1 PGY-2 physician reserved (R) position (7 total applicants)

IMPACT: For the second year in a row, IR has emerged among the most competitive primary specialties in medicine, at the same time being its newest.

ACTION: Ensure your company is well-informed on the transition from IR fellowships to residencies and the implementation of a universal curriculum for IR residents. For additional information, please contact [Jonas Nash](#), SIR director of corporate relations.

Supporting evidence-based research on sacroplasty

SIR Foundation is collaborating with BenchMarket Medical (BMM) to obtain outcomes data and procedural data on sacroplasty procedures. A total of six clinical sites were selected to participate and collect outcome data in managing sacral insufficiency fractures. To date, 15 procedures have been captured in the registry, which will continue enrolling through 2020. SIR Foundation and BMM aim to collect a total of 252 procedures in the registry by 2020.

IMPACT: The sacroplasty registry is collecting data to evaluate the effectiveness of this procedure. The data will be used to manage patient treatment and provide support for reimbursement.

ACTION: If your site completes one to two sacroplasty procedures per month, please contact [Eleanore Moyer](#), SIR Foundation director of research and grants. Learn more about the [sacroplasty registry](#).

Newly endowed GEMS program supports diversity and inclusion

As we continue to experience remarkable growth and breakthrough clinical barriers, the society, foundation, physician members and corporate partners have redoubled their commitment to diversity and inclusion within the specialty. To help solidify a diverse future for IR, Alan H. Matsumoto, MD, FSIR, and his family introduced a new, endowed grant program through SIR Foundation. The Grants for the Education of Medical Students (GEMS) Program is intended to attract medical students from diverse backgrounds to the medical profession of IR by providing scholarships to fund visiting clerkships/rotations in interventional radiology. Students who are seeking to be the first generation of physicians in their families and identify as being from racial or ethnic groups that are underrepresented in the medical field, female, or LGBTQ are eligible to apply for these scholarships, as are students who come from socioeconomically disadvantaged backgrounds.

SIR Foundation is grateful to Dr. Matsumoto, his family, and GEMS industry sponsors—Boston Scientific, Cook Medical, Gore and Associates, Penumbra and Siemens Healthineers—for supporting this exciting program.

IMPACT: The GEMS program will ease financial burdens and attract medical students from diverse backgrounds IR by providing scholarships to fund visiting clerkships/rotations in interventional radiology outside of their home institutions.

ACTION: Applications for the current cycle are being accepted now through Aug. 1. For more information visit sirfoundation.org/gems.

PRESERVE transitions to next stage

SIR and the Society of Vascular Surgery (SVS) concluded data collection for PRESERVE (**PRE**dicting the **S**afety and **E**ffectiveness of Inferio**R** **V**ena Cava Filters) on March 31, 2019, with 53 centers enrolling 1,430 subjects in the final dataset. This collaboration between SIR and SVS is the first large-scale, multispecialty, prospective clinical research trial to evaluate inferior vena cava (IVC) filter use and follow-up protocols in the United States. The following filter manufacturers participated in PRESERVE: ALN Implants Chirurgicaux (ALN Vena Cava Filters), Argon Medical Devices, Inc. (Option™ Elite Retrievable Vena Cava Filter designed and manufactured by Rex Medical), B. Braun Interventional Systems Inc. (VenaTech® LP Vena Cava Filter and VenaTech® Convertible™ Vena Cava Filter), Bard Peripheral Vascular, Inc. (DENALI® Vena Cava Filter System), Cook Incorporated (Cook Günther Tulip Vena Cava Filter), Cordis Corporation (Cordis OptEase® Retrievable Vena Cava Filter/ Cordis TrapEase® Vena Cava Filter), and Volcano Corporation (Crux® Vena Cava Filter System).

IMPACT: The study captured data regarding the safety and effectiveness of commercially available IVC filters placed in the United States. PRESERVE investigators submitted a paper on the study’s unique design and methodology to the *Journal of Vascular Surgery*. Primary endpoint calculation is anticipated to begin in 2020, and secondary endpoint calculation is anticipated to begin in 2021.

ACTION: Sites participating in PRESERVE are encouraged to maintain communication with subjects and collect follow-up data. Learn more about [PRESERVE](#).

<p>Corporate Ambassador Program</p> <p>SIR and SIR Foundation are grateful for the Corporate Ambassador Program (CAP) Partner companies that invest in the specialty and help make our missions possible.</p> <p><small>*Partner listing current as of 06/20/19</small></p>	<p>LUMINARY BTG</p>
	<p>LEADERS Boston Scientific Corporation Cook Medical</p> <p>Medtronic</p>
	<p>ADVOCATES BD Gore and Associates Guerbet Merit Medical</p> <p>Penumbra Inc. Siemens Healthineers Sirtex Medical</p>
	<p>FRIENDS Abbott AngioDynamics Argon Medical Devices Bayer Bristol-Myers Squibb Cordis, A Cardinal Health company</p> <p>Dova Pharmaceuticals Inari Medical Philips Healthcare Stryker IVS Terumo Interventional Systems</p>
	<p>ASSOCIATES AstraZeneca Pharmaceuticals LP B. Braun Interventional Systems Inc.</p> <p>Eisai Inc. Endocare United Biologics</p>



Make an impact, get involved.

The Corporate Ambassador Program (CAP) is a high-visibility, coordinated support-and-recognition program for businesses that seek more for IR, now and in the future. Ambassador companies partner with us to advance critical efforts that enhance minimally invasive patient care, promote image-guided therapies and improve patient outcomes. Learn more at sirweb.org/cap.